News & Events
Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo | Lightning Talk
- Friday November 13, 2026 | 9:35 am – 9:40 am PST
- Innovation Spotlight Stage #3
Presentation Details
Lightning Talk: Multiplex Plasma Biomarker and APOE4 Integration Predicts Amyloid-PET Status Across the Alzheimer’s Disease Clinical Continuum
Presenter: Paul Hung, PhD
Blood-based biomarkers offer a cost-effective, minimally invasive way to detect amyloid pathology in Alzheimer’s disease (AD), but ultrasensitive detection often requires expensive equipment and specialized personnel.
In this talk, we present an AD 5-plex assay simultaneously measuring key biomarkers (pTau-217, Aβ40, Aβ42, NfL, and GFAP) in just 12.5 µL of plasma. The assay is built on SPLASH™ (Solid Phase Ligation Assay with Single wasH) technology, a proximity-ligation immunoassay that combines a simple benchtop workflow with read-out on a standard 96-well qPCR instrument.
In 101 Bio-Hermes-001 samples spanning the AD clinical continuum, the AD 5-plex alone predicted amyloid PET status with an AUC of 0.92. Incorporating the APOE4 status further increased the AUC to 0.94.
These findings suggest that combining biologically complementary plasma markers with genetic risk could provide a practical, accessible way to screen patients before costly PET imaging.